Wellvana Taps Optum Veteran to Lead at Value-Based Care Crossroads

NASHVILLE, Tenn. – May 07, 2026 – Wellvana, a major force in the U.S. healthcare shift toward value-based care, has appointed Dr. David Rankey as its new Chief Medical Officer. The move signals a significant deepening of clinical leadership for a company that has already demonstrated substantial financial and operational success in a rapidly evolving market.

Dr. Rankey, a physician executive with 15 years of experience, joins Wellvana from Optum Health, where he most recently served as National Chief Medical Officer of Clinical Excellence. In that role, he was responsible for a $700 million affordability portfolio covering more than five million patients. His appointment comes as Wellvana aims to solidify its position and scale its model at what many in the industry describe as a critical inflection point for value-based care.

“David has been in the exam room, run scaled care programs with demonstrated impact, and built the kind of trust with providers that actually moves behavior,” said Wellvana CEO Susan Diamond in a statement. “That combination doesn't come along often, and it's exactly what our partners need from us.”

A Strategic Play at a Market Inflection Point

Dr. Rankey’s arrival coincides with a period of intense transformation in healthcare reimbursement. The industry is moving decisively away from the traditional fee-for-service model, where providers are paid for volume, toward value-based arrangements that reward quality outcomes and cost efficiency. As Dr. Rankey noted, “Value-based care is at an inflection point.”

This transition is no longer a theoretical exercise. The Centers for Medicare & Medicaid Services (CMS) is aggressively pushing providers toward accepting greater financial risk. Forthcoming rules for 2026 are expected to mandate participation in new models for specialists and limit the ability of Accountable Care Organizations (ACOs) to remain in one-sided risk arrangements, where they can share in savings but are not penalized for losses. This regulatory pressure is forcing healthcare organizations to move beyond proving the concept of value-based care and focus on proving its performance at scale.

Wellvana's strategic posture reflects this urgency. The company made a significant market move in March 2025 by acquiring CVS Health's Medicare Shared Savings Program (MSSP) business in an all-stock deal, making CVS Health a minority investor. That acquisition substantially expanded Wellvana's national footprint, which now serves approximately 850,000 patients through a network of health systems and independent practices across 40 states. Bringing in a leader with Dr. Rankey's experience in managing large-scale, high-risk patient populations appears to be a direct response to the demands of this expanded network and the broader market pressures.

“The models that are going to succeed aren't just the ones that save money on paper,” Dr. Rankey stated. “They're the ones where providers feel like they're part of a movement — where the work they do every day truly connects to better outcomes for their patients. That's what drew me to Wellvana.”

From the ER to the Executive Suite

Dr. Rankey brings a unique dual perspective that is highly coveted in the value-based care sector. Before moving into health system leadership, he practiced emergency medicine in Level 1 and Level 2 trauma centers, giving him a frontline understanding of the healthcare system's fractures and successes. This clinical credibility is often seen as essential for engaging physicians, who are critical to the success of any value-based initiative.

His track record in executive roles is equally compelling. During more than a decade of leading clinical strategy at Kaiser Permanente Washington and Optum Health, he built and scaled programs focused on care management, population health analytics, and quality improvement. According to Wellvana's announcement, his leadership at Kaiser Permanente was associated with significant results, including a reduction in hospital admissions by as much as 20%, a high-performance 4.5 HEDIS star rating, and care programs that generated $100 million in annual savings. This history of achieving measurable improvements in both cost and quality is precisely what value-based care enablers like Wellvana are built to deliver.

This blend of on-the-ground clinical experience and high-level strategic execution is what CEO Susan Diamond highlighted as a rare and necessary combination for guiding Wellvana’s partners through the complexities of modern healthcare delivery.

Scaling Proven Performance

Dr. Rankey joins an organization with considerable momentum. In performance year 2024, Wellvana's network of ACOs generated $337 million in gross savings for the Medicare Shared Savings Program. The company also operated the nation's top-ranked individual ACO by gross savings, with its flagship organization generating approximately $169 million in savings for Medicare. This performance placed it at the forefront of a successful year for the MSSP program, which saw ACOs generate $6.6 billion in total gross savings for Medicare.

As a “value-based care enabler,” Wellvana’s business model is to provide the infrastructure, data analytics, and expertise that hospitals, health systems, and independent primary care practices need to succeed in risk-bearing contracts. The challenge now is to replicate and scale its successes across its vastly expanded network. Dr. Rankey’s experience in overseeing affordability and clinical excellence for a population of five million patients at Optum directly aligns with this strategic imperative.

His immediate agenda includes engaging with the company’s provider partners. Dr. Rankey is scheduled to make his first public appearance for the company at the Accountable Care Symposium from May 12-14, where he will lead a roundtable discussion with winners of Wellvana’s inaugural CARE Awards, which recognize excellence in value-based care delivery.